DGAP-News: CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting
GDF-15 is a factor that is secreted by several major tumor entities and interferes with effector T cell recruitment.
- GDF-15 is a factor that is secreted by several major tumor entities and interferes with effector T cell recruitment.
- "Our tailored \'mono-followed-by-combination\' trial design allows all participating patients to access a promising, novel antibody combination therapy from the very start of the clinical trial, resulting in great patient and Investigator interest in trial participation."\nDr.
- "\nAn additional abstract on GDF-15 preclinical data will appear in the 2021 ASCO Annual Meeting Proceedings, a Journal of Clinical Oncology supplement.
- CatalYm received financial support from the EIF via the EIB-EIF Co-investment Facility, backed by the European Union through the European Fund for Strategic Investments (EFSI).\n'